Business Context and Reporting Period
This Form 6-K filing by Universe Pharmaceuticals INC covers the month of February 2024. The report details a corporate action regarding the listing status of the Company's ordinary shares on the Nasdaq stock exchange.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a listing transfer and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the transfer of the Company's ordinary shares from the Nasdaq Global Market to the Nasdaq Capital Market. The Company applied for this transfer on January 23, 2024, received approval from Nasdaq Listing Qualifications on January 30, 2024, and the transfer became effective at the opening of business on February 1, 2024.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the procedural details of the listing transfer.
Key Facts for Investor Verification
- Universe Pharmaceuticals INC shares are now listed on the Nasdaq Capital Market as of February 1, 2024.
- The transfer was approved by Nasdaq Listing Qualifications on January 30, 2024.
- This filing does not include updated financial results or operational data.